AstraZeneca (LON:AZN – Get Rating) acquired a £125 ($152.29) worth goal from equities analysis analysts at Barclays in a analysis report issued on Tuesday, Borsen Zeitung reviews. Barclays‘s worth goal would point out a possible upside of 6.51% from the inventory’s present worth.
A lot of different analysis companies additionally lately commented on AZN. Jefferies Monetary Group set a £108 ($131.58) goal worth on AstraZeneca in a report on Thursday, January fifth. JPMorgan Chase & Co. set a £135 ($164.47) worth goal on AstraZeneca in a analysis be aware on Monday. Credit score Suisse Group set a £118 ($143.76) worth goal on AstraZeneca in a analysis be aware on Friday. Deutsche Financial institution Aktiengesellschaft set a £130 ($158.38) worth goal on AstraZeneca in a analysis be aware on Thursday, December fifteenth. Lastly, Citigroup reaffirmed a “purchase” score on shares of AstraZeneca in a analysis be aware on Wednesday, November sixteenth. One equities analysis analyst has rated the inventory with a maintain score and 7 have issued a purchase score to the corporate. Based mostly on information from MarketBeat, AstraZeneca has a median score of “Average Purchase” and a consensus goal worth of £115.45 ($140.66).
AstraZeneca Worth Efficiency
AstraZeneca stock opened at £117.36 ($142.98) on Tuesday. AstraZeneca has a one 12 months low of GBX 8,214 ($100.07) and a one 12 months excessive of £118.08 ($143.86). The corporate has a debt-to-equity ratio of 88.97, a fast ratio of 0.59 and a present ratio of 0.81. The enterprise has a fifty day transferring common of £111.17 and a two-hundred day transferring common of £107.39. The corporate has a market cap of £181.85 billion and a P/E ratio of 11,177.14.
AstraZeneca Firm Profile
AstraZeneca PLC, a biopharmaceutical firm, focuses on the invention, growth, manufacturing, and commercialization of prescription medicines. Its marketed merchandise embrace Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso, and Zoladex for oncology; Brilinta/Brilique, Bydureon/Byetta, BCise, Byetta, Crestor, Evrenzo, Farxiga/Forxiga, Komboglyze/Kombiglyze XR, Lokelma, Onglyza, Qtern, and Xigduo/Xigduo XR for cardiovascular, renal, and metabolism ailments; Bevespi Aerosphere, Breztri Aerosphere, Daliresp/Daxas, Duaklir Genuair, Fasenra, Pulmicort, Saphnelo, Symbicort, and Tudorza/Eklira/Bretaris for respiratory and immunology; and Andexxa/Ondexxya, Kanuma, Soliris, Strensiq, and Ultomiris for uncommon ailments.
This immediate information alert was generated by narrative science expertise and monetary information from MarketBeat as a way to present readers with the quickest and most correct reporting. This story was reviewed by MarketBeat’s editorial workforce previous to publication. Please ship any questions or feedback about this story to firstname.lastname@example.org.
Earlier than you think about AstraZeneca, you may need to hear this.
MarketBeat retains monitor of Wall Road’s top-rated and finest performing analysis analysts and the shares they suggest to their shoppers every day. MarketBeat has recognized the five stocks that high analysts are quietly whispering to their shoppers to purchase now earlier than the broader market catches on… and AstraZeneca wasn’t on the listing.
Whereas AstraZeneca presently has a “Average Purchase” score amongst analysts, top-rated analysts consider these 5 shares are higher buys.